The five growth questions for healthcare tech
Guide · Frameworks · 6 min read · last verified 2026-07-27
A healthcare technology company sells one product to two different minds. The clinician asks whether a tool is safe, evidence-backed, and workable at the point of care. The administrator asks whether it integrates, complies, survives a security review, and earns its place in a strained budget. These two buyers do not read the same sources, trust the same signals, or put the same questions to AI assistants — and a growth plan that addresses "the buyer" as a single person will be half-right for both and convincing to neither. This vertical edition of the five growth questions therefore runs the framework on two parallel tracks, one clinical and one economic, with a shared evidence standard underneath.
One purchase, two research worlds
Call the first group clinical evaluators: physicians, nurses, therapists, lab directors, department leads — the people whose workflow the product enters and whose professional judgment sits behind its use. Call the second group economic buyers: administrators, IT and security teams, procurement, finance. In most healthtech deals both groups hold a veto, and they exercise it from different directions. The clinical side can kill a purchase the spreadsheet loves; the economic side can kill a tool the pilot ward adores.
Modern research behaviour has widened the gap rather than closed it. Each group now asks assistants its own dialect of questions, receives answers assembled from different source pools, and arrives at the decision table with a different picture of the same product. The committee dynamics are a subject of their own — AI research across the buying committee — but the planning consequence is simple and demanding: every growth question must be answered per track, because an answer that satisfies one track is invisible to the other.
The clinical track: evidence before enthusiasm
Clinicians are trained to distrust claims, and their research behaviour shows it. Their questions are concrete and consequence-shaped: how the tool behaves inside the workflow it enters, what happens when it errs, who else in the specialty uses it, and what the peer conversation actually says about living with it. They weight professional communities, society guidance, and named colleagues far above vendor material — and when they consult an assistant, they notice sourcing quality before they notice anything else.
Serving this track means publishing to the standard it applies. Describe what the product does and does not do, in workflow terms, with limitations stated plainly rather than buried. Put named clinical voices on the work: commentary signed by an advisory clinician carries the one currency this audience accepts, and expert quotes are also what assistants prefer to cite. And hold a hard line on claims: any statement about clinical benefit or outcomes belongs to evidence and regulatory processes that sit outside marketing's authority, and should reach the public only through them. Work with your clinical, regulatory, and compliance colleagues before a benefit claim ships anywhere, including a blog post — nothing in this article is guidance on what may be claimed. Nothing disqualifies a healthtech vendor in clinical eyes faster than a page that outruns its evidence.
The economic track: the operational reading
The economic buyer's questions barely overlap with the clinician's: which systems it integrates with and how painfully, what the security and privacy posture looks like under assessment, what implementation demands of already overstretched staff, what support looks like at three in the morning, how the contract flexes if the pilot disappoints. Their research runs through different territory — peer administrator networks, procurement communities, IT review practices — and their assistant queries are phrased in operations language, not clinical language.
The content this track needs is unglamorous and decisive: integration documentation an IT lead can evaluate before a single call, a security page that anticipates the assessment questionnaire instead of waiting for it, an implementation account honest about the staffing lift, support terms in plain language. Vendors underinvest here because none of it feels like marketing. All of it is marketing — it is the material from which the economic track quietly builds its shortlist.
Five questions, two columns
Threading the framework through both tracks produces the working plan, and a table shows the edition in miniature:
| Growth question | Clinical track | Economic track |
|---|---|---|
| Where are we losing buyers? | Specialty questions and peer forums where the product is absent or misdescribed | Integration and security comparisons that omit you; assistant answers on operational fit |
| What should we create? | Workflow-level documentation, plain limitation statements, named clinical commentary | Integration, security, and implementation material that pre-answers the questionnaire |
| How do we reach them? | Professional communities, society venues, specialty publications | Administrator peer networks, procurement surfaces, IT-review channels |
| Who ships it, and when? | Clinically reviewed work — slower, signed, accurate | Ops-reviewed work — faster, versioned against the product |
| Did it work? | Re-measured presence on the clinical question set | Re-measured presence on the operational question set |
The last row deserves emphasis: measurement in healthtech should be split by audience. A single blended score hides exactly the imbalance that kills deals — strong clinical visibility paired with an absent security story, or the reverse. Magrios handles this by keeping the benchmark's buyer questions tagged per track and re-scanning the same set on schedule, so clinical movement and economic movement can be read separately and honestly.
The citation bar: sourcing discipline is the strategy
Everything above rests on one cultural fact: in healthcare, a wrong public statement is not embarrassing, it is disqualifying. The tolerance for looseness that consumer categories extend to marketing does not exist here, and assistants answering health-adjacent questions reflect that caution — careful, source-heavy material travels; assertive, unsourced material does not.
The practical discipline is strict and worth writing down. Every substantive page names its sources. Every expert statement carries a name and a credential. Every factual assertion has a home someone could visit. Material that cannot meet the bar does not ship, however useful it would be. This is more restrictive than any other vertical's content operation, and that is exactly why it works as a filter: most vendors will not sustain the discipline, so the ones that do give themselves a genuine shot at becoming the reference their niche reaches for — a position nobody can promise, and nobody reaches without this work. Third-party validation compounds the effect, since assessments by named external evaluators are among the most durable sources assistants draw on — the way analyst assessments seep into AI answers is a route of its own.
Where the tracks converge
The deal closes at the point where both tracks arrive with their questions answered: the clinician satisfied the tool respects the work, the administrator satisfied it respects the institution. A healthtech growth plan succeeds when neither track hits silence on the way there — no specialty question answered only by a competitor, no security question answered only by a document that must be requested. Fintech operators will recognise the shape of this discipline; the fintech edition runs the same five questions where the binding constraint is substantiation rather than a divided audience. In healthcare the constraint is trust held to a professional standard, twice over — and the plan that honours both standards is the one whose story is already told before the committee ever convenes.